Literature DB >> 17028479

Managing multiple cardiovascular risk factors: state of the science.

Jon H Levine1.   

Abstract

Cardiovascular risk comprises genetic, lifestyle, and metabolic factors. Risk factors frequently occur simultaneously, compounding the risk for a cardiovascular event. The most commonly occurring metabolic clustering includes elevated blood pressure, dyslipidemia (high triglyceride levels and low levels of high-density lipoprotein cholesterol), and impaired glucose tolerance or type 2 diabetes mellitus. Together with visceral obesity, this clustering of risk factors is known as the metabolic syndrome. Although the definition of the metabolic syndrome and its relevance in clinical practice are the subject of discussion, there is emerging consensus about the importance of treating all risk factors early and aggressively. Recent evidence suggests that new-onset diabetes mellitus and microalbuminuria are independent risk factors that should be considered when assessing composite cardiovascular risk. Treatment should be tailored to a patient's risk profile, with consideration of the varying effects that agents of different therapeutic classes have on cardiovascular and metabolic parameters.

Entities:  

Mesh:

Year:  2006        PMID: 17028479      PMCID: PMC8109623          DOI: 10.1111/j.1524-6175.2006.05924.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  45 in total

1.  Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.

Authors:  E J Lewis; L G Hunsicker; W R Clarke; T Berl; M A Pohl; J B Lewis; E Ritz; R C Atkins; R Rohde; I Raz
Journal:  N Engl J Med       Date:  2001-09-20       Impact factor: 91.245

Review 2.  Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition.

Authors:  Scott M Grundy; H Bryan Brewer; James I Cleeman; Sidney C Smith; Claude Lenfant
Journal:  Circulation       Date:  2004-01-27       Impact factor: 29.690

3.  Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial.

Authors:  L Hansson; L H Lindholm; L Niskanen; J Lanke; T Hedner; A Niklason; K Luomanmäki; B Dahlöf; U de Faire; C Mörlin; B E Karlberg; P O Wester; J E Björck
Journal:  Lancet       Date:  1999-02-20       Impact factor: 79.321

4.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

Authors:  S Yusuf; P Sleight; J Pogue; J Bosch; R Davies; G Dagenais
Journal:  N Engl J Med       Date:  2000-01-20       Impact factor: 91.245

Review 5.  Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence.

Authors:  Earl S Ford
Journal:  Diabetes Care       Date:  2005-07       Impact factor: 19.112

Review 6.  Cardiovascular disease and the kidney. Tracking a killer in chronic kidney disease.

Authors:  Adeera Levin; Lesley Stevens; Peter A McCullough
Journal:  Postgrad Med       Date:  2002-04       Impact factor: 3.840

7.  Urinary albumin excretion. An independent predictor of ischemic heart disease.

Authors:  K Borch-Johnsen; B Feldt-Rasmussen; S Strandgaard; M Schroll; J S Jensen
Journal:  Arterioscler Thromb Vasc Biol       Date:  1999-08       Impact factor: 8.311

8.  Risk stratification in hypertension: new insights from the Framingham Study.

Authors:  W B Kannel
Journal:  Am J Hypertens       Date:  2000-01       Impact factor: 2.689

9.  Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial.

Authors:  Stevo Julius; Sverre E Kjeldsen; Michael Weber; Hans R Brunner; Steffan Ekman; Lennart Hansson; Tsushung Hua; John Laragh; Gordon T McInnes; Lada Mitchell; Francis Plat; Anthony Schork; Beverly Smith; Alberto Zanchetti
Journal:  Lancet       Date:  2004-06-19       Impact factor: 79.321

10.  Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study.

Authors:  Lars H Lindholm; Hans Ibsen; Knut Borch-Johnsen; Michael Hecht Olsen; Kristian Wachtell; Björn Dahlöf; Richard B Devereux; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Stevo Julius; Sverre E Kjeldsen; Krister Kristianson; Ole Lederballe-Pedersen; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel; Peter Aurup; Jonathan M Edelman; Steven Snapinn
Journal:  J Hypertens       Date:  2002-09       Impact factor: 4.844

View more
  2 in total

1.  Understanding of Diabetic Dyslipidemia by Using the Anion-Exchange High Performance Liquid Chromatography Data.

Authors:  Hidekatsu Yanai; Yuji Hirowatari; Kumie Ito; Hideo Kurosawa; Norio Tada; Hiroshi Yoshida
Journal:  J Clin Med Res       Date:  2016-03-20

Review 2.  Diabetic dyslipidemia: evaluation and mechanism.

Authors:  Hidekatsu Yanai; Yuji Hirowatari; Hiroshi Yoshida
Journal:  Glob Health Med       Date:  2019-10-31
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.